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Abstract: Nanoparticulate materials displaying enzyme-like properties, so-called nanozymes, are
explored as substitutes for natural enzymes in several industrial, energy-related, and biomedical
applications. Outstanding high stability, enhanced catalytic activities, low cost, and availability at
industrial scale are some of the fascinating features of nanozymes. Furthermore, nanozymes can also
be equipped with the unique attributes of nanomaterials such as magnetic or optical properties. Due
to the impressive development of nanozymes during the last decade, their potential in the context of
tissue engineering and regenerative medicine also started to be explored. To highlight the progress,
in this review, we discuss the two most representative nanozymes, namely, cerium- and iron-oxide
nanomaterials, since they are the most widely studied. Special focus is placed on their applications
ranging from cardioprotection to therapeutic angiogenesis, bone tissue engineering, and wound
healing. Finally, current challenges and future directions are discussed.
Keywords: catalytic activity; cerium-oxide nanoparticles; iron-oxide nanoparticles; nanoparticles;
nanozymes; reactive oxygen species; superparamagnetic nanoparticles; regenerative medicine;
tissue engineering
1. Introduction
Over the past three decades, research efforts focused on mimicking the functionality and structural
properties of biological enzymes [1]. The overall goal was to create “artificial enzymes” that mimic
the key functions of naturally occurring enzymes, but also display enhanced properties such as
improved stability or being more cost-efficient [2,3]. This is because the practical use of native
enzymes is hampered by several limitations. Biological enzymes possess a very short half-life, display
immunogenicity within our organism, and are highly sensitive to environmental changes [4]. As an
example, the half-lives of nanozymes were reported to be as high as several days in contrast to several
minutes for their biological counterparts [5–7]. Furthermore, they are obtained via direct synthesis or
via extraction from natural organisms [1], which are accompanied by high production costs [8].
To the present day, various attempts to create “artificial enzymes” were reported, and include
the development of metal complexes [9], polymers [10,11], supramolecular systems [12,13], and
bio-molecules [14]. Of particular interest are inorganic nanoparticles (NPs) with enzyme-like properties,
so-called “nanozymes”. While inorganic NPs may seem very different from native enzymes, they
share several features with their biological counterparts such as a similar size, an irregular shape,
or a rich surface chemistry [4]. In addition, nanoparticulate enzyme mimics display much higher
stability and large surface areas compared to biological enzymes [3]. Nanozymes, furthermore, exhibit
a high number of catalytically active surface atoms, translating into high activities—oftentimes reacting
in a more efficient manner than biological enzymes, which usually feature only one active site [1].
Additionally, nanozymes are available cost-efficiently and at an industrial scale.
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Despite having higher reactivity than biological enzymes, nanozymes display less specificity and
selectivity [4]. However, such a drawback can be overcome if nanozymes are utilized for catalytic
reactions involving small molecules (e.g., oxygen radicals or hydrogen peroxide (H2O2)), where the
steric information of native enzymes has less relevance [4].
Nanozymes are mainly employed in environmental science and biomedicine [1,4], with the latter
involving different areas ranging from cancer diagnostics to enzyme replacement, therapeutics for
neurodegenerative disorders, and cancer or anti-bacterial therapy; the reader is referred to excellent
and recent reviews in the field [4,15–18]. Recently, nanozymes are receiving increasing attention for
tissue engineering applications, since initial biological studies highlighted their antioxidant protective
effects in various cell lines [19–21].
In this review, we describe recent developments and future perspectives of nanoparticle enzyme
mimics (so-called “nanozymes”) in the field of tissue engineering and regenerative medicine. Despite a
wide range of nanomaterials including carbon, metal, and metal oxide reporting catalytic activities [22],
mainly metal oxides are explored in the context of regenerative medicine. An overview of the topics
covered is shown in Scheme 1.
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are employed as nanoparticle (NPs) olutions or labeling agents for several m m lian cell lin s,
or incorporated wi hin scaffolds such as fibrou networks or c mposites. Finally, they re evaluated
in vitro and in vivo.
Efforts using metal oxides were mainly centered around cerium-oxide (CeO2) NPs (CO-NPs) and
iron-oxide NPs (IO-NPs), which mainly include hematite (iron(III) oxide, Fe2O3) and magnetite (iron(II,
III) oxide, Fe3O4) NPs. This is due to the ability of both CO-NPs and IO-NPs to reduce reactive oxygen
species (ROS) [1,3,23]. ROS are free-radical intermediates resulting from the conversion of oxygen
into water (H2O), and consist of a superoxide anion radical (O2•−), H2O2, and a hydroxyl radical
(•OH) (Scheme 2A) [24]. Therefore, peroxidase- [25], catalase (CAT)- [26] and superoxide dismutase
(SOD)-like activities were investigated [27]. The reduction reactions are showed in Scheme 2B where
SOD catalyzes O2•− into H2O2, which can be subsequently catalyzed by CAT and peroxidase into H2O.
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efficient feature for the depletion of cancer cells which, in contrast to healthy cells, cannot survive in 
the temperature range of 42–49 °C [29,31]. Importantly, in 2007, it was reported that IO-NPs displayed 
Scheme 2. The stepwise reduction of oxygen with its free radical intermediates (A). Enzymatic reactions
of superoxide dismutase (SOD), catalase (CAT), and peroxidase (perox) to remove reactive oxygen
species (B).
The antioxidant properties of CO-NPs are known to arise from the co-existence of Ce(III) and
Ce(IV) oxidation states, which produce a redox couple responsible for their catalytic activity. Such a
switch between the III/IV valence resembles the mechanism of redox enzymes, which use metals as
co-factors to catalyze reversible redox reactions (Scheme 3) [21]. As such, reactions comprising redox
cycles between Ce(III) and Ce(IV) oxidation states make it possible for CO-NPs to react catalytically
with O2•− and H2O2, thus mimicking the function of two key antioxidant enzymes, namely, SOD
and CAT (Scheme 3A,B, respectively) [21]. Upon reaction with O2•−, H2O2 is formed while Ce(III) is
oxidized to Ce(IV). Next, Ce(IV) reacts with H2O2 to generate oxygen while being reduced back to
Ce(III). This regenerates the CO-NPs while eliminating both O2•− and H2O2 in a consecutive set of
reactions. Alternatively, a second H2O2 molecule may get reduced into H2O while oxidizing Ce(III)
into Ce(IV), thus acting as a true CAT mimic [21]. Therefore, CO-NPs could result as extraordinary
antioxidants by scavenging two abundant ROS in a repetitive manner. Due to the ability to deplete
ROS via a self-regenerati g mechanism, CO-NPs, which are also biocompatible, were explor d in the
context of inflammation and pathologies ss c ated with oxidativ stress (e.g., neurodegenerative
disorders or canc r) [21]. Naturally, such antioxidant properties were also explored in the context of
regenerative medicine.
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a particularly efficient feature for the depletion of cancer cells which, in contrast to healthy cells,
cannot survive in the temperature range of 42–49 ◦C [29,31]. Importantly, in 2007, it was reported that
IO-NPs displayed intrinsic peroxidase-like activity similar to that of horseradish peroxidase (HRP) [32].
It was the first report of a nanozyme or inorganic nanoparticle performing as an enzyme mimic.
Currently, IO-NPs also show the ability to mimic CAT-like activity. CAT, similar to HRP, belongs to
the oxidoreductase family, and both enzymes contain a porphyrin heme group as a cofactor in their
active site. The mechanisms behind the peroxidase and CAT activity are not fully understood, but it
was proposed that Fenton/Haber–Weiss mechanisms are involved (Scheme 4) [33–35]. While both
Fe2O3 and Fe3O4 NPs display HRP- and CAT-like activity, the latter display better activity than the
former [36]. Thus, as a result of their antioxidant properties, IO-NPs were also recently reported in
regenerative medicine and tissue engineering applications.
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2. Nanozymes in Regenerative Medicine and Tissue Engineering
2.1. Cardioprotection
A first example of the potential of CO-NPs for regenerative medicine was reported by the
Kolattukudy group [20]. The authors reported the first research study where CO-NPs were employed
to address stress-induced diseases in vivo. A transgenic mouse model with cardiac-specific expression
of monocyte chemoattractant protein-1 (MCP-1) was used. MCP-1 is a pro-inflammatory cytokine
which results in ischemic cardiomyopathy and activation of genes related to endoplasmic reticulum (ER)
stress. It was shown that intravenously administered CO-NPs were able to inhibit the progression of
left ventricular dysfunction and dilatation, and to decrease myocardial inflammation, pro-inflammatory
cytokine expressions, and the expression of ER stress-associated genes. It was suggested that CO-NPs
were able to block oxidative stress via their auto-regenerative antioxidant properties, thereby preventing
inflammatory disorders [20]. In a follow-up study, the Kolattukudy group assessed the ability of
CO-NPs to protect H9c2 cardiomyocytes from oxidative damage induced by cigarette smoke extract [37].
Cigarette smoke contains and generates a large amount of ROS, overwhelming the antioxidant capacity
of the heart, and leading to oxidative damage and the subsequent pathological consequences in the
cardiovascular system. To evaluate the cardioprotection of CO-NPs, the authors employed an in vitro
model where H9c2 cardiomyocytes were exposed to cigarette smoke extracts. The amounts of ROS,
nuclear factor-κB (NF-κB), and inflammatory cytokines were analyzed. NF-κB is a redox-sensitive
transcription factor that is activated by elevated ROS levels, and it is closely associated with myocardial
inflammation, cardiac remodeling, and heart failure [38]. Pre-treatment with CO-NPs before exposure
to cigarette smoke extract inhibited the depletion of critical antioxidant enzymes in vitro and diminished
the levels of ROS, NF-κB, and inflammatory cytokines [39].
Pre-treating cardiac cells with CO-NPs for oxidative stress protection was also investigated by
Pagliari and co-workers [40]. Cardiac progenitor cells (CPCs) were harvested from mouse-derived
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hearts and treated with CO-NP for 24 h. CPCs are highly relevant in regenerative medicine, since
they have the potential to match the tissue demands of a damaged heart following myocardial
infarction [41,42]. The in vitro culture of progenitor cells, however, requires the preservation of
physiological ROS levels. By adding CO-NPs to the cell culture, the authors aimed to evaluate whether
they could control the oxidative stress without harming the CPCs. The CO-NPs were floating in the
cytosol, without affecting the cells’ survival, growth, and capability to differentiate. Their antioxidant
potential was demonstrated by exposing the cells to H2O2-induced oxidative stress in a dose- and
time-dependent manner for up to seven days. The results showed ~80% and ~70% decreases in ROS
levels for 25 and 10 µg/mL CO-NP, respectively. These results are of utmost interest, since they open
the door to the creation of novel biomaterials such as CO-NP-loaded scaffolds that are able to create a
beneficial microenvironment to preserve CPCs during in vitro tissue growth.
Another area of interest is the treatment of hypertension. Hypertension is associated with
microvascular dysfunction, partially attributed to chronic inflammation and mitochondrial dysfunction,
resulting in increased ROS levels [43–45]. The effect of CO-NPs acting as antioxidants was investigated
using a spontaneously hypertensive rat model [43]. Characteristics of this rat model are its microvascular
dysfunction and excess of local ROS production. After CO-NP exposure, the oxidative stress levels
significantly decreased, being almost identical to those of a normotensive rat model that was not exposed
to CO-NPs. Furthermore, analyzing pro-inflammatory cytokines in harvested plasma suggested that
the CO-NPs altered the inflammatory signaling pathways in both rat models.
The Blough group investigated CO-NPs in a pulmonary arterial hypertension (PAH) model [46].
Since recent reports suggested that enhanced oxidative stress and apoptosis are related to the
pathological remodeling of the heart, it was hypothesized that CO-NP administration would diminish
oxidative stress and apoptosis. This fact would, in turn, attenuate PAH and right ventricular remodeling.
PAH was induced in Sprague-Dawley rats via a single injection of the toxic compound monocrotaline
(MCT), resulting in heart hypertrophy. Using pulsed-wave Doppler echocardiography, it was possible
to show that administered CO-NPs were able to diminish the changes in pulmonary flow, right
ventricular tissue weight, and wall thickness. The hypertrophic response to CO-NPs was also evaluated
at a cellular level. In agreement with the echocardiographic findings, CO-NP administration promoted
a decrease in strong indicators of PAH and right ventricular remodeling such as β-myosin heavy chain,
fibronectin expression, protein nitrosylation, protein carbonylation, and cardiac superoxide levels.
Since ventricular remodeling following PAH is related to cardiomyocyte apoptosis, the authors also
verified the accompanying diminished caspase-3 activation and reduction in serum inflammatory
markers, which are all indicators of cardiomyocytes apoptosis.
The effect of CO-NPs in MCT-induced PAH was recently investigated in combination with
mineralocorticoid receptor-antagonist spironolactone (SP), a diuretic used in chronic heart failure [47].
After treatment with 0.5 mg/kg CO-NPs, a one-fold reduction in H2O2, a 70% reduction in ROS, and a
75% reduction in nitrites were observed (Figure 1A–C). Interestingly, the co-treatment with SP did
not offer a significant additional effect on the cardiac oxidative stress. The authors also investigated
changes in endothelin-1 (ET-1) levels. ET-1 is an endothelium-derived vasoconstrictor peptide present
during pulmonary vasoconstriction, which is thought to play a role in the PAH pathogenesis [48].
Serum ET-1 levels increased nine-fold after PAH induction, and were reduced after CO-NP treatment
(Figure 1D). A 59% decrease was observed following administration of 0.5 mg/kg CO-NPs, whereas
only a 21% decrease was present when combined with SP. Since the lungs are the major site for the
production and clearance of ET-1 [49], the lung collagen content was assessed using hydroxyproline
levels, showing 60% and 86% decreases for the single and co-treatments, respectively (Figure 1E).
A lung tissue specimen furthermore showed only mild tissue affection for the CO-NP treatment
(Figure 1F,G). It was hypothesized that the CO-NPs suppress the ET-1 system through their potent
inhibitory effect on inflammatory mediators. The non-significant additive effect of co-treatment was
thought to be due to the decreasing pulmonary vasoconstriction, without changing the pulmonary
vascular histology caused by SP [50].
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IO-NPs were also evaluated in a cardioprotection context. In a first study, IO-NPs were reported
to protect hearts from ischemic damage both in vitro and in vivo [51]. Myocardial damage is ofte
caused by a lack of blood flow to the heart, a dysfunction known as myocardial ischemia. This, in turn,
leads to myocardial hypoxia which can then provoke coronary artery heart disease, angina pectoris,
or even myocardial infarction [51]. At present, there is no proven effective therapy [52], and current
treatment for myocardial ischemic injury involves the administration of several pharmaceutical drugs
such as free-radical scavengers, antioxidants, calcium channel blockers, and anti-apoptotic agents [51].
However, one of the main concerns is that pharmacologic drugs target only one particular mechanism,
while myocardial ischemic injury is associated with multiple pathological mechanisms. As an alternative
approach, the cardioprotective potential of IO-NPs was evaluated. The IO-NPs were compared to
the activity of two pharmaceutical drugs that are widely employed for the treatment of conditions
involving myocardial ischemic injury—verapamil, which works as a calcium channel blocker, and
Salvia miltiorrhiza extract, which acts as an antioxidant. The authors fabricated 2,3-dimercaptosuccinic
acid (DMSA)-modified IO-NPs in a range of small sizes and evaluated their cardioprotective potential
using a rat coronary artery ligature model [51]. The cardioprotective effect of the IO-NPs, which was
assessed in terms of left ventricular developed pressure after ischemia reperfusion, was higher than
that of both Salvia miltiorrhiza extract and verapamil. Interestingly, the cardioprotective effect was also
shown to be dependent on the IO-NPs size, but independent of the surface charge.
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Han and co-workers employed IO-NPs to prime cardiac mesenchymal stem cells (cardiac MSCs,
cMSCs) [53]. The multipotency of cMSCs is an encouraging feature; however, cardiac differentiation
in vivo remains challenging [54–56]. Research efforts focused on inducing the cMSC cardiac phenotype
in vitro by means of exogenous supplements (e.g., transforming growth factor beta 1 (TGF-β1) or
5-azacytidine), or by co-culturing them with cardiomyocytes or cardiomyoblasts [57,58]. While cMSCs
co-culturing with H9c2 cardiomyocytes showed promising results, H9c2 cells hardly express the gap
junction protein connexin 43 (Cx43) [59]. Cx43 is crucial for cMSC differentiation due to its central role
in intercellular gap junction coupling and the subsequent cell-to-cell crosstalk in co-culture [60,61].
The authors pre-loaded the H9c2 cardiomyocytes with IO-NPs, which were subsequently co-cultured
with cMSCs. It was hypothesized that, upon internalization by H9c2 cells, IO-NPs are partially ionized
into iron ions, which then trigger the gap junctional signaling cascade. It was shown that IO-NP uptake
enhanced the Cx43 expression in H9c2, while also creating functional gap junction communications
with the cMSCs. The cMSCs furthermore showed a significant increase in cardiac-specific genes
which induced cardiac phenotype development. Next, the authors used the magnetic properties
of the internalized IO-NPs to physically separate the H9c2 cells from the cMSCs (non-magnetic).
The therapeutic efficacy of the differentiated cMSCs was evaluated by injecting them into myocardial
infarction rat models. A reduced fibrotic tissue formation and superior infarct size suppression was
observed. Transthoracic echocardiography furthermore showed a decrease in both left ventricular
internal diameter at end diastole and at end systole for the cMSC group.
The group of Parivar used superparamagnetic IO-NPs to label the MSCs themselves [62].
Superparamagnetic IO-NPs are commonly used for cell tracking and as a contrast agent in MRI,
and for magnetization of cells in tissue engineering and drug targeting [63,64]. Polyethylene glycol
(PEG)ylated IO-NPs were synthesized and added to the MSCs for 48 h to obtain IO-NP-labeled MSCs.
Next, the IO-NP-labeled MSCs were injected into the heart of a heart failure rat model. For the
magnet-dependent IO-NP-labeled MSCs, a neodymium magnet was placed over the heart for 48 h. A
higher restoration of the injected fraction was observed in the magnetic-dependent group as compared
to the unlabeled MSCs and the magnet-independent groups. Since a higher fraction of IO-NPs was
retained in the heart, increased preservation of the cardiomyocytes was obtained, as well as a reduction
in fibrosis formation after heart failure.
Finally, IO-NPs are also used in the context of cardioprotection to create scaffolds for heart tissue
engineering applications. In particular, Mou and co-workers incubated DMSA-modified IO-NPs with
primary cardiomyocytes, showing internalization in a dose-dependent manner without affecting cell
viability [65]. While the internalized IO-NPs showed in vitro peroxidase-like activity able to decrease
the ROS levels, no changes in Cx43 expression could be observed (Figure 2A,D). However, the results
were different in a follow-up study by the same group [66]. This time, the DMSA-coated IO-NPs
were supplemented to primary cardiomyocytes seeded on a collagen/Matrigel scaffold (Figure 2C).
Interestingly, stronger contractions of the cell scaffolds were observed for the treatment groups. Such
contractions are an indication of intercalated discs, which are composed of gap junctions, adherent
junctions, and desmosomes between the cardiomyocytes [67]. This was confirmed using TEM, showing
the presence of the different structures (Figure 2F). Western blotting showed increased expression
of Cx43 in a dose-dependent manner, thus demonstrating the ability of IO-NPs in promoting gap
junction assembly (Figure 2B,E). As such, these results show how different functions were exerted by
the IO-NPs when comparing a two-dimensional (2D) environment [65] with a three-dimensional (3D)
environment [66].
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2.2. Therapeutic Angiogenesis
Angiogenesis, a process responsible for the formation of new blood vessels from existing ones, is
a crucial phenomenon for several physiological and pathophysiological processes [68,69]. Therapeutic
angiogenesis, which aims at promoting the formation of collateral vessels, is a novel and powerful
strategy for treating patients suffering from severe ischemic diseases such as peripheral artery disease
or myocardial infarction [70].
Currently, treatments to promote angiogenesis involve the administration of pro-angiogenic
cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF) [71,72]. However, clinical trials of growth factors including VEGF resulted in pathological
angiogenesis, thrombosis, and fibrosis [69,73,74]. Another approach for therapeutic angiogenesis
involves the transplantation of progenitor cells harvested from the bone marrow or circulating
blood [75–77]. However, clinical trials of cell transplantation so far resulted in a very poor
response [75–77].
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Since novel approaches are highly sought after, nanozymes were also explored in the context of
angiogenesis. Such approaches mainly rely on the protective antioxidant properties of nanozymes to
modulate the intracellular oxygen environment which is closely related to angiogenesis.
In a pioneering study, CO-NPs were evaluated in terms of their pro-angiogenic potential using
both in vitro and in vivo assays [69]. The authors took advantage of the oxygen-loading capacity of
CO-NPs, which was attributed to the valence state of cerium combined with the inherent defects
in the crystal lattice structure. The authors speculated that catalytically active CO-NPs would be
able to modulate the intracellular oxygen environment within endothelial cells. This would result in
endogenously stabilizing hypoxia-inducing factor 1α (HIF-1α), which would subsequently trigger
angiogenesis. The authors engineered CO-NPs of different sizes (ranging from 5 to 60 nm) and
shapes including stars [78], polygonals [79], and nanorods [80]. Additionally, CO-NPs displaying
two different Ce(III)/Ce(IV) ratios were considered and were termed CO-NP1 and CO-NP2 for high
Ce(III) and high Ce(IV) content, respectively [69]. The different CO-NPs were pre-loaded in endothelial
HUVECs (human umbilical vein endothelial cells), and the biocompatibility of the NPs was verified.
Next, the anti- and pro-angiogenic effects were evaluated in vitro employing the endothelial tube
formation assay [81]. The results, which demonstrated a significant and concentration-dependent
induction of tube formation, were further confirmed in vivo. Via the chick chorioallantoic membrane
(CAM) sprouting assays, it was possible to demonstrate ~350% and a ~250% angiogenic increases
for CO-NP1 and CO-NP2, respectively, as compared to the untreated control. The authors were also
able to demonstrate that angiogenesis was induced by a reduction of the intracellular ROS levels [82].
Interestingly, via Western blot, it was possible to estimate the amount of HIF-1α within the cytoplasm
and nucleus of the HUVECs. HIF-1α regulates the tissue local oxygen concentrations [83], which then
influence the angiogenic process. The results showed a higher amount of HIF-1α for cells treated with
CO-NP1 as compared to CO-NP2, thus demonstrating that the Ce(III)/Ce(IV) ratio in the CO-NPs
plays a crucial role in angiogenesis. It was hypothesized that such a difference may be due to the
fact that CO-NP1, due to the higher Ce(III) content, is highly deficient in oxygen and can, therefore,
catalytically act as an oxygen buffer by providing facile pathways for the release and replenishment of
intracellular oxygen. All in all, the authors were able to demonstrate the ability of CO-NPs to induce
pro-angiogenesis, and that such an activity is critically dependent upon the surface valence states.
Further research on the relevance of the Ce(III)/Ce(IV) ratio was conducted by incorporating
trivalent metal ions [84]. It was hypothesized that samarium (III) doping of CO-NPs (smCO-NPs)
would allow tuning of the Ce(III)/Ce(IV) ratio in the NPs, thus enhancing the angiogenic potential of the
NPs. The authors were able to demonstrate that smCO-NPs enhanced cell viability, proliferation, and
expression of angiogenic markers (HIF-1α and p38 mitogen-activated protein kinases) as compared to
the non-doped controls.
CO-NPs were also incorporated in scaffolds for in situ tissue engineering. In situ tissue engineering
does not incorporate cells into their materials, but rather utilizes the body’s own regenerative
capacity [85]. Polycaprolactone (PCL) scaffolds were fabricated by electrospinning, incorporating
different percentages (w/w) of CO-NPs (PCL-CO-NPs) [86]. As shown in Figure 3A, highly porous
networks of PCL-CO-NPs fibers were obtained. The biocompatibility of the composite scaffold was
firstly evaluated in vitro using MSCs and HUVECs (Figure 3B). While the effect on MSCs was marginal,
a more pronounced difference was observed for the HUVECs, showing overall enhanced viability
for PLC-CO-NP-1%. Next, analysis by means of CAM sprouting indicated increased angiogenesis
for the CO-NP containing PLC scaffolds (Figure 3C). The number of capillary junctions was highest
for PCL-CO-CP-1%, with a 3.6-fold increase, while the blood vessel diameter was highest for both
PCL-CO-CP-1% and PCL-CO-CP-2% (Figure 3D,E, respectively). Following on, the PCL-CO-NPs
were subcutaneously implanted into male Sprague-Dawley rats showing better integration with the
surrounding tissue as compared to bare PCL scaffolds. After one week of implantation, angiogenesis
was observed for all scaffolds, with a positive correlation to the CO-NP content. The expressions
of genes related to hypoxia, which are known to enhance cell proliferation and angiogenesis, were
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also investigated. The results demonstrated upregulation for both HIF-1α and VEGF (Figure 3F,G,
respectively), showing a dose-dependent hypoxia response. Since a significant inflammatory response
for PCL-CO-CP-3%, as shown by the upregulation of the inflammatory markers tumor necrosis factor
α (TNF-α) and cyclooxygenase (COX), was observed (Figure 3H,I, respectively), it was concluded by
the authors that the overall best properties were obtained when employing a CO-NP content ≤2%.
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method to cell injection, the Murohara group fabricated cell sheets which were evaluated in vivo
for therapeutic angiogenesis [70]. The cell sheets were assembled employing a magnetic force onto
MSCs pre-loaded with IO-NPs. MSCs were the cell of choice due to their pro-angiogenic potential
as a result of their ability to release of several angiogenic growth factors including VEGF, bFGF,
and stromal cell-derived factor-1α [90,91]. The MSCs were incubated with lipid-coated IO-NPs, and
multi-layered cell sheets were created, employing a magnet on the reverse side. The ability of the
as-prepared cell sheets in promoting angiogenesis was evaluated in mice subjected to unilateral hind
limb ischemia. The enhanced angiogenesis for the group implanted with the MSC-sheets was shown
by a greater degree of blood perfusion. At the microcirculation level, significantly increased tissue
capillary and arteriolar densities for harvested ischemic tissues were observed for the MSC-sheet group.
The cell viability of the cells within the MSC-sheets was also assessed. This is an important fact since
reported studies of cell transplantation via the direct syringe injection method reported cell viabilities
of only 3–5% at postoperative day seven [88,89]. The results revealed a significantly lower number of
apoptotic cells in the ischemic muscles of the MSC-sheet group as compared to the MSC-injected group.
The authors speculated that the inhibition of cell apoptosis might be a result of the suppression of ROS
production via the peroxidase-like activity. The antioxidant properties due to the IO-NPs labeling were
also assessed in terms of blood flow recovery of ischemic tissues. The results showed higher capillary
and arteriolar densities in ischemic tissues on postoperative day 21 following transplantation with the
MSC-sheets. Taken together, the as-prepared MSC-sheets with improved MSC and host cell viability
could potentially improve cell therapy for regenerative medicine in ischemic diseases.
In a follow-up study, the Murohara group constructed multi-layered cell sheets employing induced
pluripotent stem cell (iPSCs)-derived fetal liver kinase-1 positive (Flk-1+) cells [92]. Flk-1+ cells were the
cell line of choice due to their reported ability in promoting angiogenesis in a hind limb ischemia mice
model [93]. Similarly to their previous study, the authors constructed multi-layered Flk-1+ cell-sheets
but, in contrast to previous work [70], this time, the Flk-1+ cells were mixed with an extracellular matrix
(ECM) precursor embedding system (Figure 4A). A magnet was then placed on the reverse side, and
the magnetized Flk-1+ cells were subsequently assembled into multiple layers following a magnetic
force. Figure 4B shows how the obtained sheets had a nearly circular shape with a diameter of 8 mm.
The sheet was ~300 µm thick, with a “net-like pattern” structure comprising 15–20 cell layers. Next,
the Flk-1+ cell-sheets were implanted in a murine model of hind limb ischemia, and their potential
to promote angiogenesis in vivo was evaluated. Similar to their previous study, the antioxidant
peroxidase-like activity of the IO-NPs was used to enhance the cell viability of the implanted cells. Via
laser Doppler blood flow and capillary density analysis, it was possible to demonstrate the ability of the
Flk-1+ cell-sheets in promoting re-vascularization (Figure 4C–H). Furthermore, the Flk-1+ cell-sheets
enhanced the expression of both VEGF and bFGF in ischemic tissues (Figure 4I,J, respectively).
2.3. Bone Tissue Engineering
Surgical operations for the reconstruction of lost or damaged bones involve the use of autografts,
allografts, or ceramic and metallic implants. However, such methods have several drawbacks including
donor site morbidity, transmission of pathogens, and serious mismatching between the properties of
the implanted materials and the native bone [94]. Thus, novel approaches for bone repair resulting
from trauma, tumor resection, or skeletal abnormalities are highly sought after.
During the past decades, the field of bone tissue engineering emerged as a powerful alternative.
The aim is either to create new tissue in vitro or to promote the regeneration of the tissue in situ by
growing cells on scaffolds [95–97]. Thus, biomaterial-based scaffolds are conceived to support the
required cell growth, differentiation, and mineralization for tissue regeneration [98–100].
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As a result of the nanozymes’ ability to enhance cell viability and proliferation, naturally,
their potential in bone tissue engineering started to be recognized [101]. Reports in that direction
mainly focused on assessing the effects of CO-NPs and IO-NPs on cell differentiation following their
incorporation within a biomaterials scaffold. A first study was reported by Karakoti and co-workers by
exploring the effects of CO-NPs on the osteogenic differentiation of human MSCs (hMSCs) [101]. Bone
marrow-derived MSCs (BMSCs) are an interesting cell type for bone regeneration, since they are able to
differentiate into osteoprogenitor cells, while also having a central role in angiogenesis, a crucial process
for the development of a vascular network to provide the required nutrients to the newly formed
bone. To guide and stimulate the growth of bone tissue, CO-NPs were incorporated into bioactive
glass scaffolds. Bioactive glass scaffolds were the material of choice due to their interconnected porous
network and compressive strength, which is similar to that of cancellous bone [102]. In addition,
bioactive glass scaffolds were reported to promote the formation of bone matrix from primary human
osteoblasts [103]. Such bone matrix was furthermore able to mineralize in vitro without the need
for osteogenic supplements that are usually employed for other bioceramic scaffolds. Karakoti and
co-workers fabricated the 70S30C (70% SiO2, 30% CaO) bioactive glass scaffolds via a sol–gel foaming
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process, and the CO-NPs were introduced while the sol was still liquid [101]. This resulted in CO-NP
entrapment within the pore walls. The ability of the seeded hMSCs to differentiate toward the
osteogenic lineage was evaluated following alkaline phosphatase (ALP) expression after 10 days in
culture. ALP is an enzyme produced by MSCs and osteoblasts, involved in the mineralization of bone
tissue. During mineralization, hydroxyapatite crystals are formed, which propagate into the ECM
where they are deposited between the collagen fibrils [104]. The results showed the highest number
of ALP-positive cells for hMSC cultured on CO-NP-containing scaffolds, thus suggesting the highest
hMSC differentiation. Importantly, an ALP signal was obtained without the addition of exogenous
osteogenic factors (e.g., ascorbic acid, dexamethasone, or β-glycerophosphate). Next, the deposition of
ECM was evaluated by quantifying the amount of produced collagen. Following 10 days of incubation,
hMSCs produced significantly higher amounts of collagen when cultured onto CO-NP-containing
scaffolds as compared to the bare ones. The authors speculated that such beneficial effects of the
CO-NPs on the differentiation of hMSCs could be attributed to the ability of the CO-NPs to act as an
oxygen buffer.
In a different study, CO-NP-containing bioactive glass scaffolds were evaluated for their
CAT-mimicking activity. It was found that such catalytic activity was dependent on the amount
of incorporated CO-NPs [105] and the composition of the bioactive glass scaffold [106], where
phosphate-containing scaffolds displayed a lower enzymatic activity. Furthermore, CO-NPs
incorporated into bioactive glass fibers resulted in antibacterial properties toward both Gram-negative
and Gram-positive bacteria [107]. A meta-analysis of CO-NPs suggested that adsorption onto the
microbial cell wall, Ce(IV) reduction, elevated pH, and oxidative stress rendered the antimicrobial
properties of CO-NPs [108]. This would, in turn, improved the success of implanted materials by
minimizing infections. Lu and co-workers also used CO-NP-containing bioactive glass scaffolds
and, this time, different Ce/Ca ratios were evaluated [109]. Employing BMSCs, a positive
relationship between the CO-NP content and extracellular calcium deposition could be demonstrated.
The authors furthermore showed that the CO-NP-containing scaffolds induced upregulation of the
extracellular-signal-regulated kinase (ERK) pathway to promote osteogenic differentiation of the
BMSCs. Calvarium skull defects were induced in vivo and implanted with the CO-NP-containing
scaffolds (Ce/Ca ratio = 1:3) or empty scaffolds. Bone mineral density and bone volume improved
significantly when CO-NPs were incorporated into the scaffolds. Tissue staining showed increased
osteoblast formation, collagenous deposition, and biomineralization, thus highlighting the positive
effect of CO-NPs on the regeneration of new bone tissue.
BMSCs were also used by the Zheng group to assess the osteogenic potential of CO-NPs. However,
this time, titanium-based scaffolds were considered [110]. To study the effect of the Ce valence state of
the CO-NPs, coatings with high Ce(III) and high Ce(IV) content were prepared—CO-A (67.5% Ce(III))
and CO-B (78.8% Ce(IV)), respectively. Incubation with BMSCs showed increased proliferation, ALP
activity, and calcium deposition for the CO-B coating. These data, thus, enhanced the osteogenic
potential of CO-NPs with high Ce(IV) content. In a follow-up study, the same group assessed the effect
of the Ce valence state on the inflammatory response of RAW264.7 macrophages [110]. In contrast to
the bare titanium substrate, coating with CO-NPs resulted in the downregulation of pro-inflammatory
cytokines (interleukin (IL)-6 and TNF-α) and the upregulation of anti-inflammatory cytokines (IL-1ra
and IL-10). Importantly, these effects were more prominent for the CO-B coatings, highlighting the
anti-inflammatory properties of Ce(IV). The Zheng group next conducted a more in-depth investigation
of the macrophage response to Ce(IV)-dominant coatings, which resulted in the upregulation of the
reparative (M2) macrophage phenotype and the upregulation of anti-inflammatory and osteoinductive
molecules by the macrophages [111].
The effect of the Ce valence state was also evaluated by Naganuma and Traversa employing
CO-NP-containing poly-l-lactide (PLA) coatings [112]. The authors were able to demonstrate that,
while dominant Ce(IV) coatings promoted cell proliferation, dominant Ce(III) coatings resulted in a
change in cell morphology and a decrease in cell proliferation for the two studied cell lines (MSCs and
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osteoblast-like cells). As such, all in all, the results indicate that higher Ce(IV) promotes osteogenic
activity on MSCs and anti-inflammatory effect on macrophages. The antioxidant properties of CO-NPs
in the context of bone tissue engineering were also evaluated by Li and co-workers [113]. BMSCs were
seeded onto CO-NP-containing titanium surfaces, followed by exposure to H2O2. The authors were
able to show no increase in ROS levels for the CO-NP-containing substrates, thus highlighting the
potential of CO-NPs in reducing oxidative injury. Additionally, CO-NP-containing coatings were able
to counteract the inhibition of osteogenic differentiation caused by H2O2.
One of the main challenges for bone scaffolds following implantation is to achieve sufficient
blood supply. Without sufficient blood perfusion or blood vessel distribution, tissue fibrosis and
necrosis will lead to failure of the implant. Angiogenesis can be promoted by sprouting blood vessels
from the existing vasculature using endothelial cells, or new blood vessels not dependent on the
existing vasculature can be formed employing endothelial progenitor cells (EPCs) [114]. This second
phenomenon is called vasculogenesis. A first example assessing the potential of CO-NPs to induce the
formation of new vessels was conducted by coating acellular cancellous bone by a mixture of PLA
and CO-NPs [115]. The coated scaffold was evaluated by seeding a mixture of MSCs and EPCs in a
non-contacting co-culture system where MSCs and EPCs were seeded onto the apical and basolateral
compartments, respectively (Figure 5A). Increased EPC cell viability (Figure 5B) and expression of
differentiation-related genes confirmed that co-culture with CO-NP-containing scaffolds promoted
angiogenic differentiation. The results also showed an increase in VEGF expression for MSCs cultured
onto the CO-NP-containing scaffolds which would, in turn, result in augmented EPC growth and
differentiation. The increase in VEGF expression was furthermore linked to improved HIF-1α stability,
caused by increased intracellular Ca2+ concentrations (as summarized in Figure 5E), which was in
agreement with previously reported studies [116–118]. After 28 days of co-culture, tube formation
of EPCs was detected, showing a large amount of branching points and tubes. This was also tested
in vivo where MSCs were seeded onto CO-NP-containing scaffolds which were then subcutaneously
implanted. Higher vascularization was observed for the CO-NP-containing scaffolds as compared
to the bare ones (Figure 5C). To evaluate whether vascularization resulted in improved bone tissue
formation, the scaffolds were stained at six and 12 weeks following implantation. In contrast to the bare
scaffolds, immature bone tissue was formed throughout the CO-NP-containing scaffolds as shown by
Masson trichrome staining (Figure 5D). This, together with the in vitro results, indicates that increased
penetration of blood vessels as a result of the CO-NPs enhances the formation of new bone tissue
within the scaffold.
Together with osteoarthritis, cartilage injuries are a major cause of disability. A major challenge
in cartilage engineering is the harsh inflammatory response resulting from injured or arthritic joints,
which causes rejection following biomaterial implantation [119–122]. Thus, due to their ability to
scavenge ROS and nitrogen species, CO-NPs were also explored to combat inflammation in the
context of cartilage engineering [123]. In particular, bovine chondrocytes were cultivated onto a
CO-NP-containing agarose scaffold and exposed to IL-1α, which was previously shown to hamper the
growth of engineered cartilage and damage the newly formed tissue [124–126]. The results showed no
significant decrease in Young’s modulus for the CO-NP-containing scaffolds, thus suggesting tissue
preservation. Additionally, no decrease in the chondrocyte viability was observed for the treatment
groups as shown by the DNA content. However, a decrease in both glycosaminoglycan and collagen
content, which are the two main components of the ECM, suggested a limited protective effect for the
CO-NP-containing scaffolds.
Motivated by the intrinsic peroxidase-like activity of IO-NPs and the central role of H2O2 in cell
growth, IO-NPs were also investigated in the context of bone tissue engineering.
In a first example, the osteogenic potential of IO-NPs was assessed by embedding them within
calcium phosphate cement (CPC) [127]. Cements are an interesting material for bone tissue engineering
due to their paste-like application into the bone defects, followed by their ability to harden and
mineralize in situ [128]. Dental pulp stem cells (DPSCs) were used in this example since they are
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easier to obtain than BMSCs while having a similar differentiation and gene expressions [129,130].
The results showed increased cell spreading and adherence to the CPC for magnetized IO-NP-containing
scaffolds [127]. Enhanced ALP, Runt-related transcription factor 2 (RUNX2), and osteocalcin (OCN)
gene expression was also observed. By demagnetizing the IO-NPs, it was furthermore concluded that
magnetism without an external magnetic field (MF) did not affect the DPSC behavior. In a follow-up
study, an MF was applied to the IO-NP-containing CPC scaffold [131] and a nearly four-fold increase
in mineral deposition was achieved. Upregulation of ALP, RUNX2, COL1, and OCN, further showed
the MF effect on osteogenic differentiation for IO-NP-containing scaffolds.Catalysts 2019, 9, x FOR PEER REVIEW 15 of 31 
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As with CO-NPs, IO-NPs were also incorporated into bioactive glass scaffolds. IO-NP-containing
borosilicate glass scaffolds reported enhanced osteogenic differentiation of BMSCs and increased
healing capacity of a calvarial defect in a rat model as compared to the bare scaffolds [132].
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IO-NPs were also incorporated into polymeric scaffolds which were fabricated via electrospinning [133],
or via composite fabrication [134] and 3D printing [135,136]. Biocompatible polymers explored so far
include PLA [137], poly(lactic-co-glycolic acid) (PCL) [138], poly(urethane) [139], and chitosan [134]. A
drawback for polymer-based scaffolds is their low mechanical strength. As such, a promising approach is
the incorporation of osteoconductive hydroxyapatite (HA)-NPs within the scaffold. As an example, HA-NPs
were incorporated into PLA fibers fabricated via electrospinning [140]. Such a scaffold demonstrated
increased cell proliferation and osteogenesis for the pre-osteoblast MC3T3-E1 cell line. These positive
effects were further enhanced in the presence of an MF. The authors speculated that the incorporation
of IO-NPs resulted in the production of huge amounts of miniature magnetic forces within the scaffold
under the external MF, continuously stimulating osteoblast cell proliferation and differentiation. Next, the
scaffolds were implanted in a bone defect model in vivo, and the animals were kept in the presence of an
MF [141]. The effects of the scaffolds were firstly evaluated by the detection of OCN, which is an ECM
protein produced by the osteoblast cells during the formation of new bone (Figure 6A). The results showed
the highest OCN levels for animals treated in the presence of the MF for the three studied time points (i.e., 10,
20, and 30 days). Figure 6B shows clearer and denser collagen fibers upon application of the MF. Evaluation
by micro-computed tomography (micro-CT) and hematoxylin and eosin (H&E) tissue staining furthermore
showed a faster remodeling process under the MF, which was attributed to the magnetic response of the
IO-NPs incorporated in the scaffold (Figure 6C,D). In a follow-up study, the inflammatory response of
IO-NP-containing scaffolds was evaluated [142]. The macrophages showed an increased angiogenic capacity,
as well as enhanced recruitment of pre-osteoblasts, indicating improved bone regenerating potential when
exposed to the IO-NP-containing scaffold in a MF.Catalysts 2019, 9, x FOR PEER REVIEW 17 of 31 
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Components of the ECM such as collagen or gelatin were also employed to construct
IO-NP-containing scaffolds [143,144]. To improve the mechanical strength of collagen scaffolds,
a common approach is to apply plastic compression [145,146]. Their potential was evaluated both
in vitro [144] and in vivo [143], and results showed increased osteogenic differentiation of osteosarcoma
cells and enhanced bone formation within the incisor sockets of a rat model. Importantly, the beneficial
effects were enhanced in the presence of an MF. Importantly, due to the magnetic properties of the
IO-NPs, they could be used as negative contrast agents in MRI. This made it possible to track the
in vivo bone regeneration.
Metallic implants were also investigated. In this context, titanium surfaces were coated with
IO-NPs, making use of the self-polymerization of dopamine into polydopamine [147]. Improved cell
attachment, proliferation, and cell–cell interaction of BMSCs in vitro was observed for the IO-NP-coated
surfaces. ALP, OCN, and RUNX2 messenger RNA (mRNA) levels were furthermore significantly
increased for the IO-NP coating, thus indicating enhanced osteogenic differentiation. IO-NPs were
also deposited onto titanium surfaces via co-deposition with mineralized collagen [148]. In vitro
experiments showed that, when the IO-NPs were located in the outer layer of the coating (O-IO-NP),
the highest ALP activity was observed. Compared to the bare collagen coating, the IO-NPs resulted in
improved cell adhesion. Furthermore, the presence of an MF resulted in increased cell spreading, matrix
mineralization, and osteogenic-related gene expression. Enhanced internalization of the IO-NPs by
pre-osteoblasts was observed for the O-IO-NP coatings as compared to the IO-NPs located in the inner
layer or when homogeneously distributed throughout the coating. These results indicated that IO-NP
internalization by the cells could, to some extent, induce osteogenic differentiation in the presence of
the MF. This is not surprising since the Gu group previously demonstrated how the internalization of
IO-NPs by BMSCs resulted in the upregulation of osteogenic markers [149]. Furthermore, such an
upregulation by the IO-NPs took place in a dose-dependent manner.
Lastly, the effect of the IO-NP arrangement on the osteogenic differentiation of MSCs was
evaluated [150]. To do so, MFs were employed to fabricate IO-NP-containing substrates with the
IO-NPs distributed in a random or striped-like fashion. Additionally, MFs with varying strengths were
evaluated. It was shown that the striped-like arrangement was able to enhance both cell proliferation
and differentiation. Furthermore, the strength of the MF employed to arrange the IO-NPs had a
positive effect on the proliferation and differentiation of MSCs. It was speculated that, as a result of
the small size of IO-NPs, the coupling energy between the IO-NPs would then generate highly local
micro-fields able to significantly affect close-contacted objects such as the cultured cells.
2.4. Wound Healing
Successful wound healing requires an orchestrated cellular response of fibroblasts, keratinocytes,
and vascular endothelial cells. While the migration and proliferation of fibroblasts and keratinocytes
result in the restoration of the ECM, the growth of vascular endothelial cells promotes the formation of
the new vessels required to supply nutrients to the skin cells [151].
Impaired wound healing, which occurs when the ability for skin restoration of one of the three cell
types is compromised, can result in various detrimental health outcomes [152]. Two important factors
that can favor or hamper the wound-healing process are the ROS and oxygen levels [101,112,123,153,154].
While high ROS concentrations impede the course of healing, a good oxygen inflow is beneficial for
the process. As such, both CO-NP and IO-NP nanozymes, due to their ability for ROS depletion and
H2O2 reduction into oxygen, respectively, were explored for wound-healing applications.
In a first study, CO-NPs were evaluated in a cutaneous wound-healing murine model [154]. Since
cells within and surrounding wounds suffer from high levels of ROS [155], Chigurupati and co-workers
hypothesized that CO-NPs, due to their ability to scavenge ROS and nitric-oxide radicals [156], would
facilitate the proliferation of the relevant cells, which would, in turn, accelerate the wound-healing
process. The authors evaluated the ability of endothelial cells for tube formation in the presence of
IO-NPs [154]. To allow for tube formation, endothelial cells were grown in a 3D Matrigel matrix, and
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the results, as assessed by optical microscopy, indicated a three-fold increase in tube formation for cells
treated with CO-NPs. Next, the CO-NPs were evaluated in an in vivo mouse model of skin wound
healing. The CO-NPs were applied daily to the wounds via topical administration, and the size of the
wound was assessed at different time points. The results showed a marked decrease in wound size for
mice treated with the CO-NPs as compared to the controls. Further experiments to understand the
mechanism revealed that CO-NPs were able to mitigate the both accumulation of a lipid peroxidation
product and nitrotyrosine-modified proteins in the wound, thus indicating an antioxidant mechanism
of action of the CO-NPs.
Other examples of the topical administration of CO-NPs to enhance wound healing involve the
use of chitosan-coated CO-NPs applied onto an open wound rat model [157]. While the chitosan
coating was used to enhance the biocompatibility of the CO-NPs, it also resulted in enhancing the
wound healing starting from day eight following topical administration. Additionally, the coated
CO-NPs were able to heal the wound significantly faster as compared to rhEGF, which is a clinically
used wound-healing agent [158].
CO-NPs were also evaluated in the context of diabetic wound healing, since complications due
to diabetes represent one of the most challenging medical issues of the 21st century [159]. Within
this study, the CO-NPs were conjugated to microRNA with the goal to enhance the inflammatory
response [159]. MiR-146a was chosen due to its reported ability to target adapter molecules of the NF-κB
pathway, resulting in increased IL-6 and IL-8 gene expression [160–162]. The authors could show that
CO-NP or miR146a treatment alone did not have an effect on the healing rate compared to the saline
control in both mouse and pig diabetic wound-healing models. However, when using the conjugated
miR164a CO-NPs, the results were different. The healing rate improved significantly, with increased
strength and elasticity in the murine model, and decreased inflammatory and increased angiogenesis
in the porcine model. Also in the context of diabetes, a first case study of topical administration
CO-NPs in diabetic foot ulcers was reported [163]. While initial treatment with orally administered
antibacterial Trikacide drug together with a hypertonic solution dressing on the wound did not heal
the ulcers, following treatment with a CO-NP-containing gel had a different outcome. Two ulcers were
treated and healed successfully, suggesting therapeutic potential for CO-NPs in the topical treatment
of diabetic foot ulcers.
Electrospun films for wound dressings incorporating CO-NPs were also evaluated. PCL–gelatin
blends are one of the biomaterials investigated for skin tissue engineering, due to their ECM-mimicking
properties, biodegradability, and biocompatibility [164]. Rather and co-workers incorporated
~42-nm-sized CO-NPs (25% v/v 30 mM solution) into the electrospun fibers [165]. In vitro assays
showed an increase in the cell proliferation rate of fibroblasts for the CO-NP-containing fibers as
compared to the bare ones. This was correlated to the ROS-scavenging properties by quantifying
intracellular ROS levels. CO-NPs were also incorporated into PCL–gelatin fibers (<25 nm CO-NPs,
1.5% w/w) by Naseri-Nosar and co-workers [166]. A full-thickness wound model in male Wistar rats
showed almost complete healing for wounds treated with the CO-NP-containing fibers after two weeks
of treatment. In contrast, the sterile gauze control wounds were still fresh.
A different application for CO-NPs within wound healing is as tissue adhesives for wound closure.
The efficient restoration of the tissue while also minimizing the aesthetic impact following an injury
still prevails as a great challenge. While multiple treatment options including sutures, staples, and
tissue adhesives are widely available, regenerative healing of the injured tissue rather than fibrotic
healing still remains elusive [167,168]. To overcome the limitations of current passive healing processes,
focus was brought to the microenvironmental processes of the wound site, which include increased
ROS production [152,169]. Therefore, due to their antioxidant properties, CO-NPs were also used in
this context. In particular, mesoporous silica nanoparticles (MSN) coated with CO-NPs (MSN-CO-NPs)
were evaluated as novel tissue adhesives (Figure 7A) [170]. Following assessment of their catalytic
properties (Figure 7B,C), the MSN-CO-NPs were applied onto 2-cm cutaneous incisions in mice. Within
eight days, the wound area was almost repaired and furthermore displayed a smooth appearance
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(Figure 7D,F). The MSN-CO-NP-treated group also yielded higher native collagen deposition and fiber
alignment, as well as a thin epidermal thickness, implying limited scar formation (Figure 7E).Catalysts 2019, 9, x FOR PEER REVIEW 20 of 31 
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concentrations. The results, as shown by a colorimetric assay and an oxygen-sensitive electrode
(Figure 8D), demonstrate catalytic activity for the IO-NP-containing PVA fibers at all the studied
concentrations. The influence of the IO-NPs on the scaffolds was investigated in terms of fibroblast
proliferation in the presence of H2O2 at detrimental concentrations. The catalytic scaffolds supplied a
better environment for cell proliferation as shown by more than 90% cell viability following overnight
incubation with the H2O2-exposed nanofibrous dressings containing IO-NPs (Figure 8E). Importantly,
complete apoptosis was observed for cells incubated with bare scaffolds. Thus, due to their ability
to diminish H2O2 concentrations to nontoxic levels, the IO-NP-PVA membranes show potential for
wound-healing dressings.
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The Xu and Gu groups used PLA as a polymer in electrosprayed scaffolds [177]. DMSA-modified
IO-NPs were i corporated into the fibers to obtain 7.5% (w/w) loading. Fibrob a ts were added,
after which a magnetic field was applied. MF intensities of 0, 5, and 10 mT were empl yed during
the in vitro stud es (MF0-, MF5-, and MF10-groups, respect v ly). Evaluation of the xpression of
pro-angioge ic cytokines VEGF, bFG , and TGF-β1 indicated enhanced angiogenesis upon applying a
MF. Additionally, the author also assessed the potential of the conditioned medium of the fibroblasts
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grown on the scaffolds to induce angiogenesis, wound healing, and an inflammatory response. This
is of interest since it could avoid scaffold-induced fibrosis. The results showed how the conditioned
media increased the migration of naïve fibroblasts, while an overall reduced inflammatory response
could be observed. When adding the conditioned media to endothelial cells, more vessel-like tubes
were formed for the MF-exposed group (1.7-fold for MF5, and 1.6-fold for MF10 compared to MF0).
This indicates that the MF promotes the capacity to form endothelial tubes.
3. Conclusions
This review started with a brief introduction to the field of enzyme mimics based on
nanoparticulate materials, followed by highlighting the progress made in regenerative medicine
and tissue engineering applications.
While the aforementioned examples showed the progress on the development of nanozymes,
there are still important challenges that need to be addressed for nanozymes to become a reality in
the clinic.
Despite the overwhelming and increasing number of publications on nanozymes, mainly
cerium- and iron-oxide nanoparticles were explored so far. As such, there is substantial room
for future developments by exploring other well-developed nanomaterials with enzyme-like properties.
The current applications of nanozymes in regenerative medicine and tissue engineering mainly rely on
the antioxidant abilities of nanozymes with a main emphasis on ROS removal. However, since natural
enzymes are able to catalyze six different types of reactions, exploring new catalytic activities different
from redox reactions can result in novel and unexpected therapeutic applications. Additionally, it
is noted that, in addition to magnetism, other functions including optical, thermal, or fluorescence
properties arising from materials at the nanoscale should also be explored. This could open up exciting
and important new research directions. Last but not least, for such multifunctional materials, there is a
complex interplay between catalytic activity, therapeutic efficacy, and biocompatibility. All of them
are critical factors when evaluating these materials. Additional hurdles arise when nanozymes are
expected to function within our body. For example, nanozymes display distinct enzymatic properties
and kinetics depending on the microenvironment (i.e., pH, temperature, or substrate availability).
Additionally, the biological milieu (e.g., body fluids) also have an influence on their surface chemistry,
which also influences their catalytic activity. Another challenge lies in reaching the desired site of
action following intravenous, topical, or implant-mediated administration. Of utmost importance
is also to achieve a high biocompatibility. While some of the discussed examples were evaluated
both in vitro and in vivo, only one was assessed in a clinical context [163]. While important progress
was made for Food and Drug Administration (FDA)-approved tissue engineering materials [178,179],
multifunctional or composite products incorporating several materials (nanozymes and polymers), as
well as cells, require more extensive preclinical characterization.
For the reviewed IO-NPs and CO-NPs, it is noted that there is a vast variation in shape, size,
and surface coatings across the different publications, which would result in different properties
including biocompatibility [180,181]. While, following intravenous administration, both CO-NPs and
IO-NPs can be found mainly in the spleen and liver [182–184], CO-NPs are then excreted through the
feces [182], while the iron is eliminated via the metabolic iron pathway [185]. While iron is thought to be
biocompatible, it should also be noted that leaked iron ions can cause geno- and cytotoxicity [185,186].
Therefore, normalized in vivo assays and meta-analyses could provide important information regarding
their safety following administration into our bodies.
Thus, while there is still a long way to go before nanozymes can be implemented in a clinical
setting, collaborative efforts from various disciplines including materials science and bioengineering,
as well as computational studies, should accelerate the progress of this exciting field.
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